Advertisement

Diabetes and Endocrinology

Home Diabetes and Endocrinology
Use of sodium glucose cotransporter 2 inhibitors is associated with an increased risk for lower-limb amputation and diabetic ketoacidosis compared with use of glucagon-like peptide 1 receptor agonists

Higher Risk for Amputation, DKA With SGLT2 Inhibitors for T2DM

Risk increased for lower-limb amputation, diabetic ketoacidosis compared with GLP1 receptor agonists
Americans who must work longer to reach Social Security retirement age have worse measures of health in the years leading up to retirement

Pre-Retirement Morbidity Higher in Later Birth Cohorts

Worse measures of health for Americans who must work longer to reach Social Security retirement age
National Health Service England recently recommended that professionals ask all patients their sexual orientation at every opportunity

Professionals Disagree About Asking Patients About Sexuality

Article offers opposing views about recommendation in England to ask patients about sexual orientation
The U.S. Food and Drug Administration policy on added sugar labeling could be a cost-effective way of improving health

Added Sugar Labeling Could Reduce CVD, Diabetes Cases

Labeling would result in gain in quality-adjusted life-years and health care and societal cost savings
In 2015

Serious Suffering Affects Almost Half of Those Who Die Yearly

Vast majority who experience serious health-related suffering have no palliative care, pain relief
For patients with morbid obesity

Lap Sleeve Gastrectomy, RYGB Equally Effective in Weight Loss

Studies show no significant difference in BMI loss at five years between these laparoscopic procedures
Canagliflozin is associated with a reduced risk for renal and cardiovascular events for patients with type 2 diabetes and kidney disease

Canagliflozin Seems Effective for Patients With T2DM, Kidney Disease

Reductions seen in risk for kidney failure, cardiovascular disease with canagliflozin versus placebo
Liraglutide treatment for weight management is not associated with increased risk of cardiovascular events

Liraglutide Not Tied to Higher Risk of Cardiovascular Events

Findings based on post hoc analysis of phase 2 and 3 clinical trials